[Female sexual dysfunction: Drug treatment options]

Area of Science:

• Reproductive Health
• Pharmacology
• Women's Health

Background:

• Female sexual dysfunction (FSD) is a prevalent condition affecting numerous women.
• FSD encompasses three categories of multifactorial disorders.
• Current pharmacotherapeutic options for FSD are limited in efficacy and scope.

Purpose of the Study:

• To review the current landscape of pharmacotherapeutic options for female sexual dysfunction.
• To highlight recent advancements and ongoing investigations in FSD treatment.

Main Methods:

• Review of existing literature on pharmacologic treatments for FSD.
• Analysis of FDA-approved medications and off-label therapeutic strategies.
• Summary of drugs under investigation for FSD.

Main Results:

• The FDA recently approved the first agent for hypoactive sexual desire disorder in pre-menopausal women.
• Hormonal therapies (estrogen, testosterone) are widely used off-label, especially for post-menopausal women.
• Investigational drugs include phosphodiesterase inhibitors and agents targeting dopamine or melanocortin receptors.

Conclusions:

• Pharmacologic treatment for FSD is evolving, with new options emerging.
• Hormonal therapies remain a cornerstone of off-label treatment for FSD.
• Further research is exploring novel mechanisms for FSD pharmacotherapy.